MAPT and Alzheimer disease: In addition to establishing a cohort of people with preclinical AD, we are also promoting research on the predictive ability of brain amyloid using blood biomarkers such as Aβ42 and phosphorylated tau 217, which detect the brain AD pathology at the earliest stage for the future.17